Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma

Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma

Immune checkpoint inhibitors (ICIs) belong to the therapeutic armamentarium in advanced hepatocellular carcinoma (HCC). However, only a minority of patients benefit from immunotherapy. Therefore, we aimed to identify indicators of therapy response. This multicenter analysis included 99 HCC patients....

Full description

Bibliographic Details
Main Authors: Stephan Spahn, Daniel Roessler, Radu Pompilia, Gisela Gabernet, Beryl Primrose Gladstone, Marius Horger, Saskia Biskup, Magdalena Feldhahn, Sven Nahnsen, Franz J. Hilke, Bernhard Scheiner, Jean-François Dufour, Enrico N. De Toni, Matthias Pinter, Nisar P. Malek, Michael Bitzer
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
hepatocellular carcinoma
immunotherapy
biomarkers
microbiome
tumor mutational burden
Online Access:https://www.mdpi.com/2072-6694/12/12/3830

Internet

https://www.mdpi.com/2072-6694/12/12/3830

Similar Items